#Bristol Myers Squibb

Stop me if you’ve heard this one before.

What new therapies are being developed by the major players in hepatitis C pharmaceuticals?

FDA has expanded the approved uses of the hepatitis C virus regimen of Bristol-Myers Squibb’s Daklinza and Gilead’s Sovaldi (sofosbuvir).

The European Commission has approved new indications for BMS’s Daklinza to treat hepatitis with Sovaldi, with or without ribavirin.

The Indian company has become the first drug maker in the country to receive approval to manufacture daclatasvir as a treatment for...

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...

The FDA as given priority review status to BMS’s applications for new indication approvals for the hep C drug virus Daklinza.

The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Bristol-Myers Squibb’s daclatasvir, asunaprevir and beclabuvir cured high rates of hepatitis C virus (HCV) among those with genotype 1...

The European Association for the Study of the Liver has issued revised guidelines for the treatment of hepatitis C.

Twelve weeks daclatasvir and Sovaldi offered a hep C 97 percent cure rate among those with genotypes 1 through 4 who were coinfected with...

New therapies have been approved for people with genotype 1 of hep C. What about everyone else?

The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston included a trove of good news for people...

The FDA has requested additional data from BMS about the hepatitis C drug daclatasvirâ€™s use in combination with other direct-acting...